Skyhawk Therapeutics expands licensing partnership with Biogen
Category: #health  By Paroma Bhattacharya  Date: 2019-07-09
  • share
  • Twitter
  • Facebook
  • LinkedIn

Skyhawk Therapeutics expands licensing partnership with Biogen

Skyhawk Therapeutics, Inc. has recently announced the expansion of its partnership with Biogen, which was initially announced on January 4, 2019.

The expansion, which leverages on the breadth of SkySTAR™ technology platform from Skyhawk, apparently expands the exclusive license of Biogen to global intellectual property rights beyond the original alliance’s research-stage therapeutic candidates for the treatment of conditions including spinal muscular atrophy, multiple sclerosis, and additional neurological disorders.

Sources familiar with the matter informed that under the agreement, Skyhawk would receive an upfront payment from Biogen and could benefit from potential future milestone royalties and payments.

According to chief executive officer and co-founder of Skyhawk, Bill Haney, Biogen has a compelling history of drug development across a multiple range of challenging conditions. The strong scientific culture of the company has already created a series of prominent global therapeutics and the work together till date has gone extremely well. Skyhawk would expand the opportunity to work together for helping more patients with challenging unmet medical requirements, Haney added.

For the uninitiated, Skyhawk Therapeutics is focused towards developing, discovering, and commercializing therapies that use its new SkySTAR™ platform to generate small molecule drugs that deliver advanced treatments to patients.

Sources further mentioned that Merck & Co. Inc., the USA based multinational pharmaceutical company, has reportedly selected Skyhawk Therapeutics for its proficiency in the development and discovery of small molecules which modulate RNA splicing. It has agreed to finance it up to $600 million for each program target along with royalties on sales of any commercialized products resulting from their partnership.

Seemingly, the agreement would be focused on potential treatments for cancer and certain neurological diseases. The agreement would mark the first external oncology partnership of Skyhawk following two years of work on its own internal oncology target, representing a careful move into the space for which it recruited new key talents.

Source Credits: https://www.prnewswire.com/news-releases/skyhawk-therapeutics-announces-expansion-of-collaboration-agreement-with-biogen-300880506.html

http://www.bioworld.com/content/skyhawk-lands-new-rna-focused-deal-merck



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

Aino Health inks deal with 55BirchStreet to expand in German markets
Aino Health inks deal with 55BirchStreet to expand in German markets
By Paroma Bhattacharya

Reports confirm that Sweden’s Aino Health and 55BirchStreet, a Germany-based digital consulting firm, have recently signed a new partnership agreement. 55BitchStreet will sell implementation services and licenses...

Visa acquires Payworks for an integrated payment acceptance solution
Visa acquires Payworks for an integrated payment acceptance solution
By Paroma Bhattacharya

Visa, the financial services company recently announced acquisition of Payworks, the Munich-based makers of payment gateway software for the POS (point of sale). The company plans to integrate cloud-based solution of P...

MacroGenics, I-Mab team up to develop & market enoblituzumab in China
MacroGenics, I-Mab team up to develop & market enoblituzumab in China
By Paroma Bhattacharya

MacroGenics, Inc. and I-Mab Biopharma, a U.S. and China based clinical-stage biopharmaceutical company that is committed to discover and develop biologics in autoimmune and immune-oncology diseases, have recently announc...